Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

PURPOSE: To determine the dose of cetuximab that can be safely combined with irinotecan for treatment of pediatric and adolescent patients with refractory solid tumors. PATIENTS AND METHODS: This open-label, phase I study enrolled patients ages 1 to 18 years with advanced refractory solid tumors, in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Trippett, Tanya M., Herzog, Cynthia, Whitlock, James A., Wolff, Johannes, Kuttesch, John, Bagatell, Rochelle, Hunger, Stephen P., Boklan, Jessica, Smith, Amy A., Arceci, Robert J., Katzenstein, Howard M., Harbison, Christopher, Zhou, Xiaofei, Lu, Haolan, Langer, Christiane, Weber, Martin, Gore, Lia
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2009
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321093/
https://ncbi.nlm.nih.gov/pubmed/19770383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.8975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares